Antithrombin (AT) substitution: sense or nonsense?

our results are preliminary. Controlled tnals are necessary to compare this technique with traditional methods and to evaluate the optimal concentration and volume oflocal anaesthetic. The role of opioids and nonopioids, such as NSAIDs and clonidine, as adjuvants to local anaesthetic dmgs also needs to be studied. Editorial. Outpatient anaesthesia. Cadian Journal ofAnaesthesi'a 1991; 38: 8W-1. Andersen R. Krohg K. Pain as a major cause of postoperative MU-. Canadian Anaesthesia society Joumal1976; 23: 366-9. Shafer A. White PF. Urguhart ML.. Doze VA. Outpatient premedication: Use of midazolam and opioid analgesics. Anestfiesiology 1989; 71: 495-501. Epstein BS. Levy ML.. Thein MH. et al. Evaluation for fentanyl as an adjunct to thiopental-introus oxide-oxygen anesthesia for short surgical procedures. Anetdiuia Review 1975; 2: 24-29. Zuurmond WWA. van Leeuwen L. Alfentanil v isoflurane for outpatient arthroscopy. Acta Anaecthm'ologica Srandim'ra 1986; 3 0 329-31. Anaesthesia, 1998, 53 (Suppl. 2). pages 1-80 . . . . . . . . . . . . . . . . . . . . . . . . . .

[1]  T. Bayston,et al.  Antithrombin: Molecular Basis of Deficiency , 1997, Thrombosis and Haemostasis.

[2]  J. Vandenbroucke,et al.  The Leiden Thrombophilia Study (LETS) , 1997, Thrombosis and Haemostasis.

[3]  K. Bauer.  Management of Patients with Hereditary Defects Predisposing to Thrombosis Including Pregnant Women , 1995, Thrombosis and Haemostasis.

[4]  P. Kyrle,et al.  Antithrombin III Concentrates-Are they Clinically Useful? , 1995, Thrombosis and Haemostasis.

[5]  P. Reitsma,et al.  Hereditary antithrombin deficiency: heterogeneity of the molecular basis and mortality in Dutch families. , 1994, Blood.

[6]  R. Carrell,et al.  Prevalence of antithrombin deficiency in the healthy population , 1994, British journal of haematology.

[7]  M. Shimada,et al.  Modulation of coagulation and fibrinolysis in hepatic resection: a randomized prospective control study using antithrombin III concentrates. , 1994, Thrombosis research.

[8]  C. Chopin,et al.  Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. , 1993, Chest.

[9]  A. Degasperi,et al.  Antithrombin III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. , 1992, Thrombosis research.

[10]  D. Hommes,et al.  Mortality in hereditary antithrombin-III deficiency—1830 to 1989 , 1991, The Lancet.

[11]  C. Francis,et al.  Prevention of venous thrombosis after total knee arthroplasty. Comparison of antithrombin III and low-dose heparin with dextran. , 1990, The Journal of bone and joint surgery. American volume.

[12]  S. Goodnight,et al.  Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. , 1990, Blood.

[13]  C. Francis,et al.  Prevention of venous thrombosis after total hip arthroplasty. Antithrombin III and low-dose heparin compared with dextran 40. , 1989, The Journal of bone and joint surgery. American volume.

[14]  H. Bergmann,et al.  Substitution of antithrombin III in shock and DIC: a randomized study. , 1985, Thrombosis research.

[15]  P. Mannucci,et al.  Treatment of congenital antithrombin III deficiency with concentrates , 1982, British journal of haematology.